Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Share Price Crosses Above 200-Day Moving Average – Time to Sell?

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)’s share price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $47.89 and traded as high as $55.17. Global X Genomics & Biotechnology ETF shares last traded at $54.83, with a volume of 25,295 shares traded.

Global X Genomics & Biotechnology ETF Price Performance

The company has a 50 day moving average of $51.30 and a 200-day moving average of $47.89. The company has a market cap of $83.89 million, a P/E ratio of -23.43 and a beta of 1.16.

Global X Genomics & Biotechnology ETF Announces Dividend

The firm also recently declared a dividend, which was paid on Tuesday, July 7th. Shareholders of record on Monday, June 29th were issued a $0.0579 dividend. The ex-dividend date of this dividend was Monday, June 29th. Global X Genomics & Biotechnology ETF’s dividend payout ratio (DPR) is presently -27.35%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. IFP Advisors Inc raised its stake in Global X Genomics & Biotechnology ETF by 20.8% in the third quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock valued at $110,000 after purchasing an additional 489 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in Global X Genomics & Biotechnology ETF by 30.9% during the second quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock valued at $164,000 after purchasing an additional 4,615 shares during the last quarter. Sei Investments Co. grew its stake in Global X Genomics & Biotechnology ETF by 110.4% in the 2nd quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock worth $194,000 after buying an additional 12,105 shares in the last quarter. Wealth Management Partners LLC purchased a new position in Global X Genomics & Biotechnology ETF in the 1st quarter worth approximately $244,000. Finally, Creative Financial Designs Inc. ADV grew its stake in Global X Genomics & Biotechnology ETF by 4.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock worth $551,000 after buying an additional 481 shares in the last quarter. Hedge funds and other institutional investors own 56.95% of the company’s stock.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.